Hansen Medical Inc. (NSDQ:HNSN) initiated a clinical trial of its Sensei X robotic technology for the control of catheter movement in patients with ventricular tachycardia.
Hansen’s system features a flexible catheter designed to simplify and enhance catheter navigation for doctors treating patients with VT.
"We have already had a number of cases that were successful with the Sensei X robotic system that had previously failed with a conventional ablation approach," said Prapa Kanagaratum, the study’s principle investigator in prepared remarks.
The study, which is sponsored by Imperial College of Science Technology and Medicine out of the cardiology department at St. Mary’s Hospital, London, will enroll 200 patients with implantable defibrillators at up to eight European hospitals.
Doctors will study the effects of robotic ablation on reducing the frequency of VT episodes and how it affects patient mortality, length of hospital stay and quality of life. The patient follow-up is two years.
"We are pleased to provide financial support of this physician-driven study as further evidence of our commitment to developing innovative products that provide clinical improvements for our electrophysiology customers and their patients," said Bruce Barclay, Hansen Medical’s president & CEO.
Earlier this month, Hansen settled a two-year beef with the federal Securities & Exchange Commission without admitting any wrongdoing and without paying a fine.
The Mountain View, Calif.-based medical device maker said it resolved a probe into the restatement of its financial results back in 2009. The settlement calls for Hansen to "cease and desist from committing or causing violations of the disclosure, periodic reporting, books and records and internal control provisions of the federal securities laws," according to a press release.